Pagibaximab

From Self-sufficiency
Jump to: navigation, search
Pagibaximab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target staphylococcal lipoteichoic acid
Identifiers
CAS Number 595566-61-3
ATC code none
Chemical data
Formula C6462H9996N1728O2028S54
Molar mass Script error: No such module "math". g·mol−1
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.[1][2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
"-tuxi-" (tumor/cancer immunotherapy)
"-cixi-" (cardiovascular)
"-lixi-" (immune system)
"-mexi-" (melanoma)
"-baxi-" (bacterial)
Pagibaximab


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
  1. ↑ Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial agents and chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668 Freely accessible. PMID 19380597. 
  2. ↑ ClinicalTrials.gov NCT00646399 Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Pagibaximab&oldid=22676"